ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

NCT03394027 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Triple Negative Breast Cancer
Endometrial Cancer
Hormone Receptor Positive, HER2 Negative Breast Cancer

Interventions

DRUG: ONC201

Sponsor

National Cancer Institute (NCI)